Promoting Innovation Culture and Leading Technological Advancements
HONG KONG, Oct. 26, 2024 /PRNewswire/ -- The Hong Kong Applied Science and Technology Research Institute (ASTRI) showcases a range of its pioneering technologies at InnoCarnival, enhancing public awareness on innovation and technology (I&T). The nine-day exhibition, which opens today at the Hong Kong Science Park, is organised by the Innovation and Technology Commission.
"ASTRI actively supports the HKSAR Government's policy to advance I&T and develop New Quality Productive Forces. Through our annual participation in the InnoCarnival, we showcase various homegrown cutting-edge technologies, allowing public to experience firsthand the conveniences brought by smart city technologies as well as how smart manufacturing solutions drives digital transformation and new industrialisation," said Ir Sunny Lee, Chairman of ASTRI.
Visitors to ASTRI's state-of-the-art booth can test drive a Formula A virtual racing car; utilise an internationally awarded gemstone identifier to distinguish real diamonds from imitations; embark on a treasure hunt in a complete darkness with a robotic guide dog; and wear an optical see-through head-mounted display (HMD) to participate in virtual pharmacy interactive game as a pharmacist. Through these engaging experiences, visitors can explore the practical application of technologies such as cellular vehicle-to-everything (C-V2X), artificial intelligence (AI), Internet of Things (IoT) sensors, as well as digital and physical twins in daily life.
The InnoCarnival is one of the events celebrating the 75th anniversary of the founding of the People's Republic of China. Under the theme "Let's Sail with Innovation and Technology", the carnival aims to promote I&T culture, nurture the young people's interest in I&T, and attract more I&T talent in the long term. ASTRI's booth (C-11 at Yellow Zone) is located on the first floor of 12W, Science Park, presenting diverse innovations:
Additionally, to celebrate the 75th anniversary of the founding of the People's Republic of China, the Innovation, Technology and Industry Bureau and ASTRI organise public guided tours at the ASTRI Technovation Centre today, showcasing Hong Kong's I&T achievements, and highlighting the advancements and prospects in developing New Quality Productive Forces and new industrialisation.
ASTRI has arranged a variety of games and tech showcases to deepen visitors' understanding of its core technologies and applications. These include 5G time-sensitive network technology, 3D integrated circuit and their application in smart cities, radio conversation analysis system, C-V2X virtual autonomous driving game, smart dispensing cabinets, tower crane model for testing construction safety technology, and coaxial confocal 3D line scanning system.
About ASTRI
Hong Kong Applied Science and Technology Research Institute (ASTRI) was founded by the Government of the Hong Kong Special Administrative Region in 2000 with the mission of enhancing Hong Kong's competitiveness through applied research. ASTRI's core R&D competence in various areas is grouped under five Technology Divisions: Advanced Electronic Components and Systems; Artificial Intelligence and Trust Technologies; Communications Technologies; Innovative Mind, and IoT Sensing and AI Technologies. It is applied across six core areas which are Smart City, Financial Technologies, New-Industrialisation and Intelligent Manufacturing, Digital Health, Application Specific Integrated Circuits and Metaverse.
Over the years, ASTRI has nurtured a pool of research, I&T talents and received numerous international awards for its pioneering innovations as well as outstanding business and community contributions. ASTRI has transferred 1,500 technologies to the industry and has been granted over 1,100 patents in the Mainland, the United States, and other countries. For further information, please visit www.astri.org.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ASTRI Showcases Latest Technologies at InnoCarnival
ASTRI Showcases Latest Technologies at InnoCarnival
ASTRI Showcases Latest Technologies at InnoCarnival
ASTRI Showcases Latest Technologies at InnoCarnival
PROVISION Study demonstrates significant economic and resource utilization advantages in FFRangio cohort compared to invasive wire-based FFR cohort
WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Today at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference taking place at the Walter E. Washington Convention Center in Washington, DC, investigators from Gifu Heart Center and Fukuoka Sanno Hospital presented the results of the physician-initiated PROVISION1 Study. The investigators shared the first randomized controlled trial (RCT) of FFRangio outcomes compared to invasive wire-based fractional flow reserve (FFR) has met its primary endpoint and revealed significant economic and resource utilization advantages for the non-invasive FFRangio technology over traditional wire-based approaches.
The PROVISION Study included the enrollment of 400 patients across 13 centers in Japan. The principal investigators, Professor Hitoshi Matsuo from Gifu Heart Center and Professor Hiroyoshi Yokoi from Fukuoka Sanno Hospital, aimed to confirm that the physiological assessment with the wire-free angiography-based CathWorks FFRangio® System yields the same clinical treatment plans as those based on evaluation performed with invasive wire-based FFR, with no difference in their clinical prognoses. Additionally, the study aims to show that FFRangio offers economic advantages over wire-based FFR.
The FFRangio System combines artificial intelligence (AI) and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree.
The PROVISION Study is the first Japanese prospective RCT comparing the outcomes of an angio-based physiology technology in comparison to invasive wire-based physiology. Patients with intermediate coronary lesions (30-90% diameter stenosis) were randomized 1:1 to either the wire-based FFR arm, in which the treatment decision was determined based on FFR values obtained using an invasive pressure wire, or the FFRangio arm, in which the treatment decision was based on FFRangio values. Based on the functional evaluations, either revascularization (PCI) and optimal medical management (OMT) or OMT alone were selected. For patients who underwent PCI, a post-PCI physiological assessment was performed using the respective technology, and patients will be followed clinically for at least one year.
Professor Yokoi shared, "The results from the post-PCI assessments performed on patients who underwent PCI and OMT, planned to be analyzed and reported after the completion of one-year follow-up, can provide the very much needed insight on optimal cut-off(s) for post-PCI FFR values, and provide the clinical evidence necessary to encourage routine post-PCI physiology assessment."
Professor Matsuo stated, "The results of this study are groundbreaking for coronary artery disease diagnostics in Japan. FFRangio offers a non-invasive alternative that not only matches the diagnostic accuracy of traditional wire-based FFR but also improves operational efficiencies and reduces costs for healthcare providers."
Key findings from the study include:
CathWorks President & CEO Ramin Mousavi added, "This significant milestone validates our mission of transforming how coronary artery disease is diagnosed and treatment through innovation. The results from the PROVISION Study have officially kicked off a new era in physiology, underscoring FFRangio as the new standard of care and potential to drive better patient outcomes while delivering tangible economic and resource utilization benefits to healthcare systems."
ABOUT CATHWORKS
CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on X and LinkedIn.
1.
Prospective Randomized trial of clinical Outcomes of angiography-based fractional flow reserve guidance Versus wIre-baSed fractIOnal flow reserve guidance (PROVISION) study is an investigation of the Utility of Coronary Angiography (FFRangio) in Comparison to Coronary Fractional Flow Reserve (FFR) in the Determination of Treatment Planning and the Clinical Prognosis in Patients with Chronic Phase Coronary Artery Disease
Investors:
Mike Feher
mike.feher@cath.works
Media:
Sarita Monico
sarita.monico@cath.works
Photo - https://mma.prnasia.com/media2/2541276/CathWorks_PressReleaseCard_OCT27_V1.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint
